Business context and reporting period
Lucid Diagnostics Inc. filed this unaudited Form 10-Q for the three months ended March 31, 2024. Lucid, a majority-owned subsidiary of PAVmed Inc., is commercializing EsoGuard, an esophageal DNA test, and EsoCheck, a sample-collection device, for detection of esophageal precancer and cancer in at-risk patients.
Financial performance and liquidity
Amounts below are in millions of dollars, except per-share data.
| Metric | Q1 2024 | Q1 2023 |
|---|---|---|
| Revenue | $1.001 | $0.446 |
| Cost of revenue | $1.656 | $1.338 |
| Gross loss | $(0.655) | $(0.892) |
| Operating loss | $(10.792) | $(14.317) |
| Net loss attributable to Lucid | $(10.612) | $(16.247) |
| Net loss attributable to common stockholders | $(18.108) | $(16.247) |
| Basic and diluted loss per share | $(0.40) | $(0.40) |
| Net cash used in operating activities | $(12.612) | $(7.120) |
- Revenue increased about 124%, principally from EsoGuard testing performed in Lucid’s own CLIA laboratory. Gross margin remained negative, but improved to approximately negative 65% from negative 200%.
- Operating expenses, including cost of revenue, were $11.793 million, down from $14.763 million. Lower general and administrative costs, particularly stock-based compensation and professional fees, and lower R&D costs contributed to the reduced operating loss.
- The common-stockholder loss includes a $7.496 million deemed dividend associated with the Series A and A-1 preferred-stock exchange; it is not an additional operating cash outflow.
- Cash was $24.769 million at quarter-end, versus $18.896 million at December 31, 2023. Financing activities provided $18.522 million, primarily from preferred-stock issuance; operating and investing activities used $12.612 million and $0.037 million, respectively.
- Current assets were $27.583 million and current liabilities $19.977 million, yielding working capital of approximately $7.6 million. Current liabilities include the convertible note at its $13.140 million fair value.
- The secured convertible note had $10.936 million of face principal and a $13.140 million fair value at March 31. It bears 7.875% interest, matures March 21, 2025, is secured by Lucid’s and its subsidiaries’ assets, and is subject to scheduled repayments and financial covenants. Lucid reported compliance with the covenants.
Material changes versus the prior comparable period
- Revenue rose by $0.555 million, while cost of revenue increased by $0.318 million; gross loss narrowed by $0.237 million.
- Operating loss narrowed by $3.525 million. General and administrative expense declined by $2.830 million, and R&D declined by $0.392 million; sales and marketing expense increased slightly.
- Operating cash use worsened by $5.492 million despite the lower net loss. The filing attributes cash movement in part to changes in working-capital balances, including payments to PAVmed.
- Lucid issued $18.165 million gross of Series B preferred stock in March, exchanged all outstanding Series A and A-1 shares into Series B, and recorded the $7.496 million deemed dividend. Common shares outstanding increased from 42.330 million at year-end to 46.747 million at quarter-end.
Outlook, commentary, and risks
- Management expects recurring losses and negative operating cash flow in the near future. The filing states that substantial doubt exists about Lucid’s ability to continue as a going concern for one year after the financial statements are issued.
- Management says continued operations depend on obtaining broader government and private insurer reimbursement, growing direct contracting with self-insured employers, and raising capital or refinancing debt. The filing gives no revenue or profitability guidance.
- In May 2024, Lucid issued approximately 11,634 Series B-1 preferred shares for $11.6 million gross proceeds. The shares have a $0.7228 conversion price; together with the March financing, the company reported approximately $29.8 million in gross proceeds from the two offerings.
- Series B preferred shares are voting securities, senior to common stock in liquidation, convertible at an initial $1.2444 price, and carry specified stock dividends equal to 20% of conversion shares on each of the first and second anniversaries. These terms, and the lower Series B-1 conversion price, may result in dilution.
- Convertible-note installment payments can be settled in shares at a price linked to market VWAP, subject to a $0.30 floor, creating further potential dilution. Subsequent to quarter-end, through May 9, Lucid reported issuing 1,139,851 shares to settle note principal and interest.
- The PAVmed management-services fee increased from $0.75 million to $0.83 million per month, effective January 1, 2024. PAVmed also received 3,331,771 Lucid shares in January to settle approximately $4.675 million of fees and reimbursements.
- The FDA’s April 2024 laboratory-developed-test rule is not expected to immediately change Lucid’s regulatory strategy: management says EsoGuard qualifies for continued enforcement discretion because it was marketed before May 6, 2024 and is approved by New York’s laboratory evaluation program. Regulatory and reimbursement outcomes remain risks.
- Other disclosed risks include market acceptance, ability to obtain financing, dependence on PAVmed, regulatory changes, and the costs of commercialization and clinical evidence development. Lucid reported no pending legal proceedings it believes are reasonably likely to have a material impact.
Key facts for investors to verify
- Whether EsoGuard testing volume, collections, and payer reimbursement improve enough to support revenue growth and reduce negative gross margins.
- Cash runway and the company’s ability to meet the note’s installment obligations, maintain its financial covenants, and refinance or repay the note due March 2025.
- The potential dilution and economic effects of Series B and B-1 conversion terms, preferred dividends, note conversions, and equity-based payments to PAVmed.
- Whether the reported continued FDA enforcement discretion and New York approval remain applicable as regulatory requirements evolve.
- Whether commercial expansion and reimbursement efforts can address the filing’s stated substantial doubt about going concern.